Tempest Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Matthew Angel
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2000 Sierra Point Parkway Brisbane CA United States of America 94005
- IPO Date
- Nov 12, 2012
- CIK
- 0001544227
- Website
- tempesttx.com
- Similar Companies
- Business
- Tempest Therapeutics, Inc. Tempest Therapeutics, Inc. (Nasdaq: TPST) is a clinical-stage biotechnology company focused on developing targeted and immune-mediated small molecule therapeutics for cancer treatment. The company advances a pipeline of oral product candidates including amezalpat (TPST-1120), a selective PPARα antagonist for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and cholangiocarcinoma (CCA); TPST-1495, a dual EP2/EP4 prostaglandin E2 receptor antagonist for solid tumors and familial adenomatous polyposis (FAP); and TREX-1, an enzyme modulating innate immune response in tumors. Founded in 2011 and headquartered in Brisbane, California, Tempest operates primarily in the United States with global clinical collaborations; it functions as a subsidiary of Inception Sciences, Inc. and targets oncology markets through direct tumor killing, immune activation, or combined mechanisms. Recent developments include a collaboration with F. Hoffmann-La Roche Ltd for amezalpat's global Phase 1b/2 study in first-line HCC, yielding positive data with a six-month median overall survival improvement versus standard care; FDA Orphan Drug and Fast Track designations for amezalpat in HCC; and a U.S. FDA Study May Proceed letter for TPST-1495's Phase 2 trial in FAP under National Cancer Institute funding. In November 2025, Tempest entered a definitive all-stock agreement to acquire clinical-stage CD19/BCMA dual-CAR T programs (TPST-2003) from Factor Bioscience Inc., expanding its pipeline for extramedullary disease; the deal anticipates runway extension to mid-2027 via preclosing equity financing and Factor investment, with leadership transition to Matt Angel, Ph.D. as President and CEO. Additional 2025 updates encompass a $8.35 million registered direct offering, Q3 financial results showing $7.5 million cash position, and plans for amezalpat's Phase 3-ready pivotal study in first-line HCC pending resources.
Company News
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Tempest signs related-party R&D pact, reshapes leadership
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
New Strong Buy Stocks for April 10th
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock